{"id":"br1400-3","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297976","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BR1400-3 works by inhibiting the angiotensin-converting enzyme 2 (ACE2), which plays a crucial role in the renin-angiotensin system. This inhibition leads to a decrease in angiotensin II levels, resulting in vasodilation and reduced blood pressure.","oneSentence":"BR1400-3 is a small molecule that targets the renin-angiotensin system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:41.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07373613","phase":"PHASE2","title":"A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2026-03-01","conditions":"Essential Hypertension","enrollment":330},{"nctId":"NCT06889064","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-09-24","conditions":"Essential Hypertension","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BR1400-3","genericName":"BR1400-3","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BR1400-3 is a small molecule that targets the renin-angiotensin system. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}